Literature DB >> 16187886

Executive functioning and speed of processing in phenylketonuria.

Shelley Channon1, Caroline Mockler1, Philip Lee2.   

Abstract

Treated phenylketonuria (PKU) has been linked to dopaminergic depletion in the dorsolateral prefrontal cortex, potentially leading to selective executive impairment. White matter abnormalities may lead to generalized slowing of information processing. These 2 hypotheses were evaluated in adults with PKU on a lifelong diet. Those with PKU were significantly slower than the control group regardless of working memory load on an n-back task and marginally slower regardless of trial type (inhibitory or noninhibitory) on a flanker task. There were no significant differences in speed on object alternation learning or perceptual judgment tasks. There were no group differences in accuracy on any task. These findings do not appear consistent with the selective executive hypothesis. A cognitive slowing account may prove more informative in adults with PKU, but more evidence is needed. The findings suggest that continuous dietary management is a fairly successful strategy in terms of cognitive outcome for adults. Copyright (c) 2005 APA, all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16187886     DOI: 10.1037/0894-4105.19.5.679

Source DB:  PubMed          Journal:  Neuropsychology        ISSN: 0894-4105            Impact factor:   3.295


  20 in total

1.  A randomized, placebo-controlled, double-blind trial of supplemental docosahexaenoic acid on cognitive processing speed and executive function in females of reproductive age with phenylketonuria: A pilot study.

Authors:  S H L Yi; J A Kable; M L Evatt; R H Singh
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2011-10-14       Impact factor: 4.006

2.  Tackling frontal lobe-related functions in PKU through functional brain imaging: a Stroop task in adult patients.

Authors:  Benedikt Sundermann; Bettina Pfleiderer; Harald E Möller; Wolfram Schwindt; Josef Weglage; Jöran Lepsien; Reinhold Feldmann
Journal:  J Inherit Metab Dis       Date:  2011-04-14       Impact factor: 4.982

3.  The influence of blood phenylalanine levels on neurocognitive function in adult PKU patients.

Authors:  A Bartus; F Palasti; E Juhasz; E Kiss; E Simonova; Cs Sumanszki; P Reismann
Journal:  Metab Brain Dis       Date:  2018-06-12       Impact factor: 3.584

4.  Effects of dietary management of phenylketonuria on long-term cognitive outcome.

Authors:  Shelley Channon; Galya Goodman; Sally Zlotowitz; Caroline Mockler; Philip J Lee
Journal:  Arch Dis Child       Date:  2006-10-26       Impact factor: 3.791

5.  Correlation of age-specific phenylalanine levels with intellectual outcome in patients with phenylketonuria.

Authors:  Krista S Viau; Heidi J Wengreen; Sharon L Ernst; Nancy L Cantor; Larissa V Furtado; Nicola Longo
Journal:  J Inherit Metab Dis       Date:  2011-05-10       Impact factor: 4.982

6.  A cross-sectional study of docosahexaenoic acid status and cognitive outcomes in females of reproductive age with phenylketonuria.

Authors:  Sarah H L Yi; Julie A Kable; Marian L Evatt; Rani H Singh
Journal:  J Inherit Metab Dis       Date:  2011-02-09       Impact factor: 4.982

Review 7.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

8.  Processing speed and executive abilities in children with phenylketonuria.

Authors:  Alicia L Janos; Dorothy K Grange; Robert D Steiner; Desirée A White
Journal:  Neuropsychology       Date:  2012-08-06       Impact factor: 3.295

9.  Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU.

Authors:  J J Moyle; A M Fox; M Arthur; M Bynevelt; J R Burnett
Journal:  Neuropsychol Rev       Date:  2007-04-05       Impact factor: 7.444

Review 10.  Phenylketonuria: a review of current and future treatments.

Authors:  Naz Al Hafid; John Christodoulou
Journal:  Transl Pediatr       Date:  2015-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.